Kanada - enska - Health Canada

omega laboratories limited - octreotide (octreotide acetate) - solution - 500mcg - octreotide (octreotide acetate) 500mcg - miscellaneous therapeutic agents

Kanada - enska - Health Canada

omega laboratories limited - octreotide (octreotide acetate) - solution - 200mcg - octreotide (octreotide acetate) 200mcg - miscellaneous therapeutic agents

Kanada - enska - Health Canada

omega laboratories limited - ciprofloxacin - solution - 2mg - ciprofloxacin 2mg - quinolones

Kanada - enska - Health Canada

omega laboratories limited - fluconazole - solution - 2mg - fluconazole 2mg - azoles

Kanada - enska - Health Canada

omega laboratories limited - famotidine - solution - 10mg - famotidine 10mg - histamine h2-antagonists

Kanada - enska - Health Canada

omega laboratories limited - famotidine - solution - 10mg - famotidine 10mg - histamine h2-antagonists

Ástralía - enska - Department of Health (Therapeutic Goods Administration)

omegapharm - cefepime -

Ástralía - enska - Department of Health (Therapeutic Goods Administration)

omegapharm - cefepime -

Írland - enska - HPRA (Health Products Regulatory Authority)

epax as - omega-3-acid ethyl esters 90 - capsules, soft - 1000 milligram

Bandaríkin - enska - NLM (National Library of Medicine)

trygg pharma inc - omega-3-acid ethyl esters (unii: d87ygh4z0q) (omega-3 fatty acids - unii:71m78end5s) - omega-3-acid ethyl esters 900 mg - omtryg™ (omega-3-acid ethyl esters) capsules, usp, is indicated as an adjunct to diet to reduce triglyceride (tg) levels in adult patients with severe (≥500 mg/dl) hypertriglyceridemia. usage considerations: patients should be placed on an appropriate lipid-lowering diet before receiving omtryg and should continue this diet during treatment with omtryg. laboratory studies should be done to ascertain that the lipid levels are consistently abnormal before instituting omtryg therapy. every attempt should be made to control serum lipids with appropriate diet, exercise, weight loss in obese patients, and control of any medical problems, such as diabetes mellitus and hypothyroidism, that are contributing to the lipid abnormalities. medications known to exacerbate hypertriglyceridemia (such as beta blockers, thiazides, estrogens) should be discontinued or changed if possible prior to consideration of triglyceride-lowering drug therapy. limitations of use: the effect of omtryg on the risk for pancreatitis has not